S/GSK1349572, a new integrase inhibitor for the treatment of HIV: Promises and challenges

Expert Opinion on Investigational Drugs

Volumn 20, Issue 4, 2011, Pages 537-548

  Lenz, Johannes Carl Christoph ^a   Rockstroh, Jürgen Kurt ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

antiretroviral therapy; HIV; HIV therapy; integrase; integrase inhibitor; S GSK1349572

Indexed keywords

5 HYDROXY 2 METHYL 6,10 DIOXO 3,4,6,9,9A, 10 HEXAHYDRO 2H 1 OXA 4A 8A DIAZA ANTHRACENE 7 CARBOXYLIC ACID 2,4 DIFLUOROBENZYLAMIDE; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ETRAVIRINE; INTEGRASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MULTIVITAMIN; ONE A DAY; PLACEBO; S GSK 1349572; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG DETERMINATION; DRUG DOSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INFECTION; INSOMNIA; LIPOPROTEIN BLOOD LEVEL; MENTAL DISEASE; MONOTHERAPY; NIGHT SWEAT; NONHUMAN; PHARMACODYNAMICS; PHOSPHATE BLOOD LEVEL; PRURITUS; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SOMNOLENCE; SORE THROAT; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VITAL SIGN;

ANTHRACENES; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS;

EID: 79952692134     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.562189     Document Type: Review

References (51)

1. A study to determine the safety and efficacy of once daily raltegravir compared to twice daily raltegravir (MK-0518-071). Available from: http://clinicaltrials.gov/ct2/show/NCT00745823 [Last accessed 28 October 2010]
2. Vispo E, Barreiro P, Maida I, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010;11:197-204
3. Fun A, Van Baelen K, van Lelyveld SF, et al. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity. J Antimicrob Chemother 2010;65:2300-4
4. Phase 3, randomized, double-blind study to evaluate the safety and efficacy of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 versus efavirenz/emtricitabine/ tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naive adults. Available from: http://clinicaltrials. gov/ct2/show/NCT01095796 [Last accessed 24 October 2010]
5. Study of the safety and efficacy of elvitegravir/emtricitabine/tenofovir disoproxil fumarate/GS-9350 (QUAD) versus atripla(R) in HIV infected, antiretroviral treatment-naive adults. Available from: http://clinicaltrials. gov/ct2/show/NCT00869557 [Last accessed 24 October 2010]
6. German P, Warren D, West S, et al. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010;55:323-9
7. Johns B, Kawasuji T, Taishi T, et al. The Discovery of S/GSK1349572: a once daily next generation integrase inhibitor with a superior resistance profile. 17th Conference on Retroviruses and Opportunistic Infections; 2010; Paper no. 55
8. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999;52:351-69
9. Brown PO. Integration of retroviral DNA. Curr Top Microbiol Immunol 1990;157:19-48 (Pubitemid 20223375)
10. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005;4:236-48 (Pubitemid 40372557)
11. Li M, Mizuuchi M, Burke TR Jr, Craigie R. Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J 2006;25:1295-304
12. Prada N, Markowitz M. Novel integrase inhibitors for HIV. Expert Opin Investig Drugs 2010;19:1087-98 Excellent review of available integrase inhibitors as well as those in clinical development.
13. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50 (Pubitemid 30070911)
14. Mouscadet JF, Delelis O, Marcelin AG, Tchertanov L. Resistance to HIV-1 integrase inhibitors: a structural perspective. Drug Resist Updat 2010;13:139-50 Detailed review of the pharmacologic mechanism of integrase inhibitors and resistance.
15. Kawasuji T, Fuji M, Yoshinaga T, et al. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. Bioorg Med Chem 2006;14:8420-9
16. Marchand C, Johnson AA, Karki RG, et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble doublemutant (F185K/C280S). Mol Pharmacol 2003;64:600-9 (Pubitemid 37048563)
17. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000;97:11244-9
18. Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010;54:254-8 Thorough analysis of pharmacokinetics and safety in healthy adults.
19. Min S, Song I, Borland J, et al. Pharmacokinetics (PK) and safety in healthy subjects of S/GSK1349572, a next generation, once-daily HIV integrase inhibitor (INI) [poster No. WEPEA099]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
20. Song I, Min S, Borland J, et al. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharm 2010: published on 20 May 2010, doi:10.1177/ 0091270010371113
21. GSK1349572 Mass Balance Study. Available from: http://clinicaltrials.gov/ ct2/show/NCT00828763 [Last accessed 15 October 2010]
22. Song I, Patel A, Min S, et al. Evaluation of antacid and multivitamin (MVI) effects on S/GSK1349572 pharmacokinetics (PK) in healthy subjects [poster No. A1-1305]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
23. Patel P, Song I, Borland J, et al. S/GSK1349572, a next generation HIV integrase inhibitor, pharmacokinetics are not affected by omeprazole in healthy adults [abstract No. H-943]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010
24. Song I, Borland J, Chen S, et al. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next generation integrase inhibitor, S/GSK1349572 [poster no. 616]. 17th Conference on Retroviruses and Opportunistic Infections; 2010
25. Song I, Min S, Borland J, et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010: published on 25 June 2010, doi: 10.1097/QAI. 0b013e3181e67909
26. Song I, Min S, Borland J, et al. The effect of etravirine anlone and with boosted protease inhibitors on the pharmacokinetics of the integrase inhibitor, S/GSK1349572 [abstract No. 26]. 11th International Workshop on Clinical Pharmakology of HIV Therapy; 2010
27. GSK1349572 drug interaction study with efavirenz. Available from: http://clinicaltrials.gov/ct2/show/NCT01098526 [Last accessed 15 October 2010]
28. Drug interaction study between GSK1349572 and tipranavir/ritonavir in healthy volunteers (ING). Available from: http://clinicaltrials.gov/ct2/show/ NCT01068925 [Last accessed 15 October 2010]
29. GSK1349572 drug interaction study with fosamprenavir/ritonavir. Available from: http://clinicaltrials.gov/ct2/show/NCT01209065 [Last accessed 15 October 2010]
30. Underwood M, Vavro C, Ptak R, et al. Activity of the next generation integrase inhibitor S/GSK1349572 and two first generation inhibitors across a broad panel of HIV subtype isolates in PBMCs and MDMs [poster No. MOPE0032]. 18th International AIDS Conference; 2010
31. Sato A, Seki T, Kobayashi M, et al. In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572 [poster No. H-932]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
32. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 7th Conference on Retroviruses and Opportunistic Infections (CROI); 16-19 February 2010; San Francisco
33. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro virology of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2010. [Epub ahead of print]
34. Underwood M, Johns B, Sato A, et al. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy [poster No. WEPEA098]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
35. Charpentier C, Larrouy L, Collin G, et al. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS 2010: published on 4 September 2010, doi: 10.1097/QAD.0b013e32833f9e36
36. Lalezari J, Sloan L, Dejesus E. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naive HIV-1-infected patients [abstract No. TUAB105]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
37. Song I, Chen S, Lou Y, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients [abstract No. WEPEB250]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 2009
38. Arribas J, Lazzarin A, Raffi F, et al. Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naive adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276) [abstract No. THLBB205]. 18th International AIDS Conference; 2010
39. Rockstroh J, Felizarta F, Maggiolo F, et al. Once-daily S/GSK1349572 combination therapy in antiretroviral-naive adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276). J Int AIDS Soc 2010;13(Suppl 4):O50
40. Eron J, Durant J, Poizot-Martin I, et al. Activity of next generation integrase inhibitor (INI) S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961) [abstract No. MOAB0105]. 18th International AIDS Conference; 2010
41. Eron J, Livrozet JM, Morlat P, et al. Activity of integrase inhibitor, S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of VIKING study (ING112961). J Int AIDS Soc 2010;13(Suppl 4):O51
42. Clotet B, DeJesus E, Lazzarin A, et al. HIV integrase genotypic and phenotypic changes between day 1 and day 11 in subjects with raltegravir resistant HIV treated with S/GSK1349572: results of VIKING study [poster No. TUPE130]. 18th International AIDS Conference; 2010
43. Clotet B, Katlama C, Lalezari J, et al. HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for subjects experiencing virologic failure on raltegravir (RAL) in the VIKING study (ING112961). International HIV and Hepatitis Drug Resistance Workshop; 8-12 June 2010; Dubrovnik Croatia
44. Lou Y, Min S, Chen I, et al. Meta-analysis of safety for short-term dosing of an HIV Integrase inhibitor, S/GSK1349572, from seven clinical studies [poster No. H-931]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009
45. Chen S, Min A, Peppercorn J, et al. S/GSK1349572 thorough QT/QTc study: a single supratherapeutic dose of S/GSK1349572 does not prolong the QTcF interval [abtract No. A1-2014]. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010
46. A study to evaluate the effect of GSK1349572 on iohexol and para-aminohippurate clearance in healthy subjects. Available from: http://clinicaltrials.gov/ct2/show/NCT01214993 [Last accessed 15 October 2010]
47. GSK press release issued 21 July 2009, Cape Town, South Africa. Available from: http://www.gsk.com/media/pressreleases/2009/2009-pressrelease-10080.htm [Last accessed 20 October 2010]
48. GSK press release issued 16 April 2009, London UK & Philadelphia, US. Available from: http://www.gsk.com/media/pressreleases/2009/2009-pressrelease- 10041.htm [Last accessed 20 October 2010]
49. ViiV Healthcare press release issued 22 July 2010, Vienna, Austria. Available from: http://www.viivhealthcare.com/media-room/press-releases/2010-07- 22.aspx [Last accessed 20 October 2010]
50. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009;83(22):11440-6
51. Delelis O, Malet I, Na L, et al. The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009;37(4):1193-201